الولايات المتحدة · منصات وبيانات · MarketBeat
Axsome Therapeutics Sees AUVELITY Prescription Surge After Alzheimer’s Agitation Launch

ملخص مفصل
Axsome Therapeutics (NASDAQ:AXSM) executives said growth in new prescriptions for AUVELITY and an expanded sales team are positioning the company for further growth following the drug’s launch for Alzheimer’s disease agitation. Speaking at the UBS Biopharma Conference in London, Chief Financial Off
يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (www.marketbeat.com)




